Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis.
Sep 2026· Biochimica et biophysica acta. Molecular cell research· pp.
120224
· 0 citations· 50 references
Medicine
TL;DR
Findings identify UMS as a candidate DDI2/NRF1-axis modulator that potentiates BTZ-induced cytotoxicity and delays functional proteasome recovery in BTZ-resistant malignant lymphoma cells.
Abstract
Proteasome inhibitors such as bortezomib (BTZ) are potent against hematological malignancies, but acquired resistance remains a major obstacle to durable clinical responses. DNA damage-inducible 1 homolog 2 (DDI2)-mediated processing of nuclear factor erythroid 2-related factor 1 (NRF1) contributes to adaptive proteasome restoration after inhibition, and nelfinavir (NFV) is the best-characterized small-molecule inhibitor of DDI2. Since previous studies have focused primarily on aspartic protease inhibitors, and several serine protease inhibitors share structural similarities with NFV, we screened selected serine protease inhibitors to modulate the DDI2/NRF1 axis. Among them, Upamostat (UMS), a clinically tested urokinase-type plasminogen activator inhibitor, altered BTZ-induced NRF1 processing, as reflected by a reduced CF/UF ratio, in U937 cells, whereas another urokinase inhibitor, UK-371804, had no such effect, suggesting that this activity was not a general consequence of urokinase inhibition. TSA showed that UMS increased the thermal stability of DDI2, supporting a direct interaction, and docking analysis suggested its accommodation within the retroviral protease-like domain of DDI2. In BTZ-resistant U937 (BTZ-R) cells, basal NRF1 mRNA expression and proteasome activity were elevated. UMS enhanced BTZ-induced reactive oxygen species generation, caspase activation, Annexin V positivity, and loss of cell viability, with stronger synergistic effects in BTZ-R cells than in parental cells. Although UMS did not suppress the early induction of NRF1 or proteasome-subunit transcripts, it significantly delayed recovery of chymotrypsin-like and caspase-like proteasome activities after BTZ washout. These findings identify UMS as a candidate DDI2/NRF1-axis modulator that potentiates BTZ-induced cytotoxicity and delays functional proteasome recovery in BTZ-resistant malignant lymphoma cells.
Findings identify enhanced NRF1-mediated proteasome adaptation as a feature of GC resistance and highlight the need for highly selective DDI2 inhibitors to evaluate DDI2-NRF1 targeting as a strategy to improve PI efficacy in drug-resistant solid cancers.
Atsumi Ota, M. Kawai, Rin Himura et al.· Biochemical and Biophysical...· 0 citations
The vision is to establish JAK inhibition as a tractable strategy for restoring checkpoint sensitivity across solid tumors, providing the foundation for a biomarker-driven randomized phase 2 trial in checkpoint-refractory disease.
Rana Mckay, L.-J. Wei, Yu-Wei Chen et al.· The Oncologist· 0 citations
GPX4 is identified as the principal mediator of MLN4924-induced ferroptosis and dual targeting of GPX4 transcription and activity represents a promising therapeutic strategy for GBM, establishing that dual targeting of GPX4 transcription and activity represents a promising therapeutic strategy.
Zhou Jing, Fangyuan Wang, Hao Li et al.· Carcinogenesis· 0 citations
Discoidin domain receptor 1 (DDR1), a collagen-activated receptor tyrosine kinase, is essential for tumor cell proliferation, invasion and drug resistance. Our study demonstrated that the expression and phosphorylation of DDR1 were associated not only with the poor outcome of non-small cell lung cancer (NSCLC), but als...
Xue-Qin Chen, Juan Shen, Zhi-Fei Xu et al.· International Journal on Bio...· 0 citations
How selective modulation of protein degradation governs adaptive resistance to RAS inhibition governs adaptive resistance to RAS inhibition and provide a framework for developing rational combination strategies to improve the durability of RAS-targeted therapies in PDAC is defined.
Cassandra S. Markham, Ilze M. Olivi Gomes, Yi Di et al.· Cancer Research· 0 citations
Findings highlight the novelty of KYNU as a therapeutic target and support the development of KS79356 as a potential treatment strategy for TNBC progression and metastasis.
Maha Alamodi Alghamdi, Hemali Deshpande, Ashish Kumar et al.· Medical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.